Lori Rudolph-Owen, Ph.D., is an accomplished C-suite biotech executive and board member, with over 26 years of biotech and pharma experience.  She is currently the Chief Development Officer at a 4:59 NewCo, a 5AM Ventures Company where she is accountable for the strategic development, operational execution and potential partnering of the company’s early development portfolio.

Previously, Lori served as the Chief Operating Officer of Senda Biosciences, an emerging Flagship biotech company, leading operations of the R&D and platform functions and developing Senda’s clinical trials and regulatory capabilities. Prior to joining Senda, Lori was the Chief Development Officer at Goldfinch Bio where she was accountable for the strategic development and operational execution of the portfolio. Lori built the development organization from the ground up and drove GFB-887, a small molecule Trpc5 inhibitor, and GFB-024, a monoclonal CB-1 inverse agonist, from late-stage discovery through IND submission and into Ph2 proof of concept clinical development.  While at Goldfinch, Lori was an integral member of the Executive Team responsible for the adjustment of the portfolio and optionality considerations for financing and strategic alternatives. 

Prior to Goldfinch, Lori served as Vice President of Portfolio Management and Assessment at TESARO, Inc., where she built and led the portfolio development teams responsible for the US and EU submissions and approvals of VARUBI® and ZEJULA®, as well as the filing of multiple investigational new drug (IND) applications. Before TESARO, Lori held positions of increasing leadership responsibility at Pfizer, AMAG Pharmaceuticals, MGI Pharma (now Eisai), Vertex and Millennium. Lori received her B.A. in Biology from Carroll University and her Ph.D. in Cell Biology from Vanderbilt University’s School of Medicine as well as completing a postdoctoral fellowship in the Department of Biochemistry also at Vanderbilt University School of Medicine.